Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.31 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188262 | 0.83 | — | — | |
| SCHEMBL31507952 | 0.82 | MEN1 (0.30) | — | |
| SCHEMBL23612185 | 0.80 | — | — | |
| SCHEMBL3432373 | 0.80 | SIGMAR1 (0.39) | — | |
| SCHEMBL3246939 | 0.80 | SIGMAR1 (0.36) | — | |
| SCHEMBL7217188 | 0.75 | MEN1 (0.46) | — | |
| SCHEMBL17506671 | 0.75 | FAAH (0.40) | — | |
| SCHEMBL21847657 | 0.74 | GAA (0.47) | — | |
| SCHEMBL24884453 | 0.71 | KIT (0.33) | — | |
| SCHEMBL31018625 | 0.70 | RET (0.38) | TEAD1TEAD4TEAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743453-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | Pretzel Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015178-A1 | MODULATORS OF MITOCHONDRIAL DNA REPLICATION | PRETZEL THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2024083208-A1 | KIF18A PROTEIN INHIBITOR | 杭州邦顺制药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117917405-A | KIF18A protein inhibitors | 杭州邦顺制药有限公司 | 2024-04-23 | — | — | CN | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| CN-115348957-A | Compounds and compositions for treating diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-4085051-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | IDH1 2417/4885TEAD1 824/4885TEAD4 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.